Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Abstract 1592: Pulsatile Myc expression as a source of Myc heterogeneity in cancer cells

View through CrossRef
Abstract Myc is the most commonly amplified oncogene, and is known to play critical roles in cancer establishment and maintenance. Myc expression heterogeneity has also been linked to cancer drug resistance; however, the source of this heterogeneity remains poorly characterized. Even in isogenic cancer cell lines, we found that Myc is one of the most heterogeneously expressed transcription factors at the single-cell level. This heterogeneity is independent of cell cycle progression, local cell density, and p53/p21 signaling. To elucidate the source and duration of Myc heterogeneity, we endogenously tagged Myc with a fluorescent protein and used long-term live-cell imaging techniques to monitor Myc expression over time at single-cell resolution. Surprisingly, we found that Myc expression is pulsatile, explaining why Myc expression appears heterogeneous at a given point in time. Furthermore, we found that Myc dynamics are heterogeneous, and the dynamics are not always heritable. Additionally, Myc pulse amplitude is correlated with the duration of G1 and the overall cell cycle, suggesting that the pulses may be a mechanism for escaping many chemotherapy agents. Finally, we show that Myc pulses are primarily transcription-driven and controlled by at least one negative feedback loop. Our findings demonstrate for the first time that Myc expression is pulsatile, and provide insights into Myc regulation in cancer. Citation Format: Chad Liu, Karen Gascoigne. Pulsatile Myc expression as a source of Myc heterogeneity in cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1592.
American Association for Cancer Research (AACR)
Title: Abstract 1592: Pulsatile Myc expression as a source of Myc heterogeneity in cancer cells
Description:
Abstract Myc is the most commonly amplified oncogene, and is known to play critical roles in cancer establishment and maintenance.
Myc expression heterogeneity has also been linked to cancer drug resistance; however, the source of this heterogeneity remains poorly characterized.
Even in isogenic cancer cell lines, we found that Myc is one of the most heterogeneously expressed transcription factors at the single-cell level.
This heterogeneity is independent of cell cycle progression, local cell density, and p53/p21 signaling.
To elucidate the source and duration of Myc heterogeneity, we endogenously tagged Myc with a fluorescent protein and used long-term live-cell imaging techniques to monitor Myc expression over time at single-cell resolution.
Surprisingly, we found that Myc expression is pulsatile, explaining why Myc expression appears heterogeneous at a given point in time.
Furthermore, we found that Myc dynamics are heterogeneous, and the dynamics are not always heritable.
Additionally, Myc pulse amplitude is correlated with the duration of G1 and the overall cell cycle, suggesting that the pulses may be a mechanism for escaping many chemotherapy agents.
Finally, we show that Myc pulses are primarily transcription-driven and controlled by at least one negative feedback loop.
Our findings demonstrate for the first time that Myc expression is pulsatile, and provide insights into Myc regulation in cancer.
Citation Format: Chad Liu, Karen Gascoigne.
Pulsatile Myc expression as a source of Myc heterogeneity in cancer cells [abstract].
In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13.
Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1592.

Related Results

Abstract 4761: Investigation of the role of N-MYC in lung neuroendocrine carcinoma
Abstract 4761: Investigation of the role of N-MYC in lung neuroendocrine carcinoma
Abstract Small cell lung cancer and large cell neuroendocrine carcinoma are classified as high-grade neuroendocrine tumors of the lung, representing extremely agg...
<i>MYC</i> rearrangement but not extra <i>MYC</i> copies is an independent prognostic factor in patients with mantle cell lymphoma
<i>MYC</i> rearrangement but not extra <i>MYC</i> copies is an independent prognostic factor in patients with mantle cell lymphoma
Mantle cell lymphoma (MCL) with MYC rearrangement (MYC-R) is rare and little is known about the importance of MYC extra copies (EC) in the absence of MYC-R in MCL patients. This st...
Improving immunotherapy in high-grade B-cell lymphoma
Improving immunotherapy in high-grade B-cell lymphoma
MYC is a transcription factor that upon deregulation acts as an oncogene. Cancer patients with MYC overexpression face significant worse outcomes to treatment with (immuno)chemothe...
Abstract 4773: MYC associated transcriptional heterogeneity at the single cell level
Abstract 4773: MYC associated transcriptional heterogeneity at the single cell level
Abstract Background: Tumor heterogeneity allows cancer cells to adapt to microenvironmental stress and resist therapies. ...
Abstract 1872: Targeting MYC-driven medulloblastoma using inhibitors of glutamine metabolism.
Abstract 1872: Targeting MYC-driven medulloblastoma using inhibitors of glutamine metabolism.
Abstract Medulloblastoma is the most common malignant brain tumor in children. Currently, treatment consists of surgical resection, chemotherapy, and whole brain and...

Back to Top